Alivus Life Sciences Reports Q2 Revenue Of ₹682 Crore Vs ₹590 Crore YoY

Market snapshot: Alivus Life Sciences Limited reported a 16.0% YoY increase in quarterly revenue from operations for Q2, reaching ₹682 crore compared to ₹590 crore in the corresponding prior-year period. Top-line expansion was accompanied by substantial operational margin improvement and net profit growth.

Data Snapshot

• Q2 Revenue from Operations reached ₹682 crore, up 16.0% YoY.
• Q2 Operating EBITDA rose 47.0% YoY to ₹285.1 crore with margins expanding to 41.8%.
• Q2 Net Profit (PAT) increased 51.3% YoY to ₹196.8 crore.
• Cash and cash equivalents stood at ₹1,011.6 crore with zero debt as of September 30, 2026.

What's Changed

• Revenue from operations increased by 16.0% YoY to ₹682 crore from ₹590 crore.
• Operating EBITDA margin expanded by 880 bps YoY to 41.8%.
• Net profit margin expanded by 680 bps YoY to 28.9%.

Key Takeaways

• Top-line growth of 16.0% YoY was supported by 20.8% YoY growth in the non-GPL API business segment.
• Disproportionate jump in EBITDA (+47.0% YoY) highlights operational leverage and favorable product mix.
• Balance sheet liquidity remains strong with ₹1,011.6 crore in cash and cash equivalents.
• The business maintains zero debt, offering flexibility for strategic growth initiatives.

SAHI Perspective

The operational divergence between revenue growth of 16.0% and EBITDA growth of 47.0% underscores strong operating leverage. As incremental higher-margin CDMO revenues and non-GPL API volume kick in, fixed costs are absorbed effectively, leading to record EBITDA margins.

Market Implications

Strong operational metrics reinforce positive sentiment around specialized API and CDMO players. Continued strategic deployment into formulation development supports higher long-term earnings quality and structural valuation support.

Trading Signals

Market Bias: Bullish

Revenue growth of 16.0% YoY alongside a 51.3% jump in net profit to ₹196.8 crore and EBITDA margins reaching 41.8% highlights robust earnings quality.

Overweight: Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing (CDMO)

Trigger Factors:

• Sustained quarterly EBITDA margins above 35%
• Commercial scaling of CDMO platform following IQGenX acquisition
• Quarterly execution in non-GPL API product portfolio

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian API and CDMO industry benefits from global supply chain diversification and sustained demand across chronic therapeutic areas such as oncology, central nervous system, and cardiovascular treatments. Specialty API producers with vertically integrated capabilities continue to achieve superior operating leverage.

Key Risks to Watch

• Raw material and key starting material price fluctuations
• Regulatory compliance requirements across global export markets
• Foreign exchange rate fluctuations affecting overseas realizations

Recent Developments

Alivus Life Sciences acquired a 76% stake in IQGenX Pharma for ₹9.12 crore in August 2026 to expand into advanced formulation development and CDMO services. In September 2026, the company incorporated a wholly owned subsidiary in Brazil, followed by acquiring a 9.21% stake in Torrent Urja 19 in October 2026.

Closing Insight

With record operating margins, a cash cushion above ₹1,000 crore, and a debt-free balance sheet, Alivus Life Sciences possesses the capital flexibility required to drive its specialty API and CDMO strategic roadmap.

High Performance Trading with SAHI.